Avenue Therapeutics Announces Agreement With The FDA On The Study Design And Analysis Approach Of The Phase 3 Safety Study For IV Tramadol
Portfolio Pulse from Benzinga Newsdesk
Avenue Therapeutics has announced an agreement with the FDA on the study design and analysis approach of the Phase 3 safety study for IV Tramadol.
July 25, 2023 | 12:34 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Avenue Therapeutics' agreement with the FDA on the Phase 3 safety study for IV Tramadol could potentially accelerate the drug's approval process.
The agreement with the FDA on the study design and analysis approach of the Phase 3 safety study for IV Tramadol is a significant step for Avenue Therapeutics. This could potentially accelerate the drug's approval process, which would be a positive development for the company and could positively impact its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100